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Signalingine that mediates its effects through a receptor composed of TGF-β receptor type
II (TGFBR2) and type I (TGFBR1). The TGF-β receptor can regulate Smad and nonSmad signaling pathways,
which then ultimately dictate TGF-β's biological effects. We postulated that control of the level of TGFBR2 is a
mechanism for regulating the speciﬁcity of TGF-β signaling pathway activation and TGF-β's biological effects.
We used a precisely regulatable TGFBR2 expression system to assess the effects of TGFBR2 expression levels
on signaling and TGF-β mediated apoptosis. We found Smad signaling and MAPK–ERK signaling activation
levels correlate directly with TGFBR2 expression levels. Furthermore, p21 levels and TGF-β induced apoptosis
appear to depend on relatively high TGFBR2 expression and on the activation of the MAPK–ERK and Smad
pathways. Thus, control of TGFBR2 expression and the differential activation of TGF-β signaling pathways
appears to be a mechanism for regulating the speciﬁcity of the biological effects of TGF-β.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionTransforming growth factor β (TGF-β) is a secretedmultifunctional
cytokine that regulates a variety of cellular processes including growth
inhibition secondary to G1/S phase arrest, differentiation, apoptosis,
immunosuppression, stimulation of connective tissue deposition,
secondary induction of angiogenesis, and probably maintenance of
genomic stability. TGF-β induces these effects by activating the TGF-β
receptor, a heterodimeric complex composed of type I (TGFBR1) and
type II (TGFBR2) subunits, which are both serine–threonine kinases
with single transmembrane domains [1]. Both TGFBRI and TGFBR2
appear to be essential for TGF-β induced effects on the cell [2,3]. The
TGF-β receptor is activated through a sequence of events that is
initiated by the TGFBR2 subunit binding to the activated TGF-β ligand.
The activated TGFBR2 associates with TGFBRI, and phosphorylates a
glycine–serine rich sequence in TGFBRI. TGFBRI is then activated and
can phosphorylate downstream targets [4]. The TGF-β receptor
complex activates both the Smad signaling pathway, which includes
Smad2, Smad3, and Smad4, and nonSmad signaling cascades (e.g.search Center, 1100 Fairview
7 1107; fax: +1 206 667 2917.
iotech, 54 Steamwhistle Drive,
ll rights reserved.PI3K/AKT, p38MAPK, MAPK–ERK, JNK, etc.) to produce the full
spectrum of TGF-β responses [5–7].
With regard to the nonSmad signaling pathway, TGF-β can activate
a variety of nonSmad signaling pathways, including the MAPK, JNK,
p38MAPK, NF-κB, RhoA, and PI3K pathways. TGF-β can regulate the
nonSmad signaling pathways both directly and indirectly. For
instance, direct physical interactions between the TGF-β receptor
and TAB1 (TAK1-binding protein 1), which can regulate TAK1 (TGF-β
Activated Kinase 1) and p38MAPK, and PI3K/AKT, have been shown
[8]. Other nonSmad signaling pathways are also clearly TGF-β res-
ponsive but, in most cases, it has not been shownwhether the effect is
a direct or indirect effect of TGF-β. The nonSmad signaling pathways
have been implicated in regulating TGF-β mediated apoptosis [8,9],
extracellular matrix production [10–12], and differentiation [11,13].
The Smad signaling pathway is more completely understood than
the nonSmad signaling pathways that are activated by the ligand
bound TGF-β receptor. Ligand binding to the TGF-β receptor complex
results in TGFBRI-mediated phosphorylation of Smad2 and Smad3 on
two serine residues in a conserved Ser-Ser-X-Ser motif located at the
C-terminus of the R-Smads [14,15]. Phosphorylation of these serine
residues activates the signaling pathway and is required for the
function of Smads in transcription factor complexes [16,17]. The
phosphorylated Smad2 and Smad3 bind to Smad4, and the complex
can then translocate into the nucleus to function as a transcription
factor complex. The details of this pathway have been the subject of a
recent review (see [18]).
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linear mechanism, it is now clear that the TGF-β signaling pathways'
effects on the biological responses of a cell depend on the intensity
and duration of the activation of the pathways [19]. Indeed, a
substantial number of studies have demonstrated that the TGF-β
signaling pathways are regulated by a variety of mechanisms that
control the cellular localization, phosphorylation state, and expression
levels of the post-receptor signaling elements [19,20]. Moreover, these
studies have provided a plausible explanation for why the cell state
and cell type, referred to as the “cellular context” can have a profound
effect on theway inwhich TGF-β affects a cell [21–23]. Recent data has
shown that the degree of activation of the TGF-β signaling pathways is
subject to regulation by a large number of intracellular and
extracellular agonists and antagonists, including decorin, Smad7,
Smurf, SARA, etc. [24,25].
The discovery of these regulatory mechanisms demonstrates that
not only is the absolute activation state of the pathway important for
determining TGF-β's effects on cells but that the degree of pathway
activation and the duration of pathway activation is also likely
important. In fact, it is plausible that the paradoxical effects of TGF-β
on tumor cells could be at least partly explained through differences in
the intensity of activation of the pathways or by differential activation
of Smad vs. nonSmad signaling pathways. Regulation of the expres-
sion levels of TGFBR1 and TGFBR2 may be a mechanism through
which the activation state of the TGF-β signaling pathways can be
regulated [8]. Consistent with this model is the recent demonstration
that levels of TGFBR1 have been shown to correlate with an increased
risk of colorectal cancer [26].
In order to assess whether the regulation of TGFBR2 expression
could be a mechanism for determining the response of cells to TGF-
β, we generated a system using the RheoSwitchR inducible gene
expression system to regulate the expression of TGFBR2. We have
found that the level of TGFBR2 affects the ability of TGF-β to induce
p21 and apoptosis in the V-400 colorectal cancer cell line. In addi-
tion, TGF-β's ability to activate the MAPK pathway is directly
dependent on the expression level of TGFBR2. These results
demonstrate that the regulation of the receptor level for TGF-β is
a potential mechanism for determining the speciﬁcity of the res-
ponse of a cell to TGF-β.
2. Materials and methods
2.1. Cell lines and inhibitors
V-400 is a microsatellite stable (MSS), TGF-β resistant colon
cancer cell line, which was kindly provided by James K.V. Willson
(UT Southwestern Medical School, Dallas, TX). It carries biallelic
missense TGFBR2 mutations that inactivate the endogenous recep-
tor, and it has an intact Smad signaling pathway [27]. The V-400
cell line was grown in Dulbecco's Modiﬁed Eagle Medium (Gibco,
Grand Island, NY). The media was supplemented with 10% FBS
(Cambrex, East Rutherford, NJ). The MEK1/2 inhibitor U0126 (Cat#
662005), and the PIK3 inhibitor LY294002 (Cat# 440204) were
obtained from Calbiochem (San Diego, CA). The Smad7 plasmid
was kindly provided by Neil Bhowmick (Vanderbilt University,
Nashville, TN).Fig. 1. Schematic representation of the p5004 vector. The functional elements2.2. Inducible gene expression system
The inducible system used in this project was developed by
RheoGene, Inc. (Norristown, PA), now Intrexon Corporation (Blacks-
burg, VA), and is a highly engineered system based on a modiﬁed
version of the ecdysone receptor (EcR) [28,29]. Important modiﬁca-
tions of this system include mutations in the ecdysone receptor to
increase potency to synthetic diacylhydrazine agonists; trans-
positioning of the VP16 activation domain and the Gal4 DNA binding
domain as fusions to the RXR and EcR components, respectively;
and development of potent and bioavailable synthetic agonists. Two
agonists, RG-102240 and RG-115819, were used in these studies.
They are closely related diacylhydrazine analogs, with the latter
being slightly more potent. These modiﬁcations signiﬁcantly im-
prove the precision of the transgene expression regulation by the
synthetic agonist.
A single construct carrying both the RheoSwitchR receptor
genes and an HA-tagged TGFBR2 transgene was made. The TGFBR2
transgene was inserted into the cloning site present in the lenti-
viral vector p5004, provided by RheoGene (Fig. 1). The TGFBR2
transgene was obtained from the vector pRC/CMV kindly provided
by Dr. Sandford Markowitz (Case Western Reserve University,
Cleveland, OH) [27]. The TGFBR2 gene was released from its
original backbone using the enzymes NotI and EcoRI and then
treated with Klenow. After cloning the TGFBR2 transgene into the
p5004 vector, plasmids were screened for inserts with the correct
orientation and were conﬁrmed to carry a wild-type TGFBR2 trans-
gene by sequencing.
A lentivirus carrying the TGFBR2 transgene was produced in the
Gene Therapy core lab at the Fred Hutchinson Cancer Research
Center using a 293T-based packaging cell line. V-400 cells were
infected with 0.5 ml of viral supernatant. The cells were incubated
for 24 h with the viral supernatant in the presence of polybrene.
The viral supernatant was then removed and Blasticidin (6 μg/ml)
was added into the complete media (DMEM in the presence of 10%
FBS). The transduced cells were then subjected to cloning by limiting
dilution. An evaluation to identify clones that displayed mini-
mal expression in the baseline state but showed adequate induction
of TGFBR2 after treatment with RG-115819 was performed in dif-
ferent clonal populations. The control cells were treated with DMSO
vehicle alone.
2.3. Luciferase reporter assays
In order to evaluate TGF-β-mediated transcription, the cell lines
were transiently transfected with the p3TP-lux reporter (kindly
provided by Joan Massagué, Memorial Sloan-Kettering Cancer Center,
New York, NY) or with the CAGA reporter assay (kindly provided
by Bert Vogelstein, Johns Hopkins University, Baltimore, MA) conco-
mitantly with the pRL-TK reporter construct (Promega, Madison, WI).
The cells were treated with TGF-β1 (10 ng/ml), and luciferase activity
was evaluated 48 h after transfection using the Dual Luciferase
Reporter Assay System (Promega, Madison, WI) with a Veritas
luminometer (Turner Biosystems, Sunnyvale, CA). The p21 expression
was evaluated using a luciferase reporter assay (kindly provided by
Dr. Xiao-Fan Wang's Laboratory) [30]. The luciferase activity wasin the vector are shown, including the location of the TGFBR2 transgene.
Fig. 2. Assessment of TGF-β signaling in representative clones of V-400 after
transduction with the inducible TGFBR2 transgene. V-400R2 clones 1 and 2 display
a linear dose–response from 0–1.0 μM of RG-102240 with the greatest increase in
3TP-Lux activity occurring between 0 μM and 0.8 μM. 3TP-Lux activity was detected at
low concentrations of RG-102240. Note that clone 1 has a wider dose–response range
than clone 2.
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transfections were performed using FuGENE 6 (Roche, Basel, Switzer-
land) following the protocol provided by the manufacturer. A 3:1
FuGENE-DNA ratio was used.
2.4. FACS analysis
V-400R2 and V-400 cells treated for 48 h with RG-115819 and
TGF-β1were used for these studies. The cells were collected after being
brieﬂy treated with trypsin (0.125%) to detach them from the ﬂasks,
washed in media with 20% FBS (4 °C) followed by 1× PBS (4 °C), and
thenﬁxed in 3% formaldehyde for 15min. The cellswere then incubated
with 10% normal horse serum for 30min, washedwith PBS 3 times, and
incubated with an anti-HA antibody (1:100, Cat # 2367 Cell Signaling,
Danvers, MA), followed by incubation with a goat-anti-mouse second-
ary antibody labeled with ﬂuorescein (FITC) (1:100, Cat#:115-095-146,
Jackson ImmunoResearch,West Grove, PA). The cells were thenwashed
with PBS (3 times) and subjected to FACS analysis using FACScan
(Becton Dickenson, Franklin Lakes, NJ). The results were analyzed using
CellQuest software (Becton Dickenson, Franklin Lakes, NJ).
2.5. Western blotting
Cell lysates were prepared using RIPA buffer supplemented with
a complete protease inhibitor cocktail (Roche) and phosphatase
inhibitor cocktails 1 and 2 (Sigma-Aldrich, St. Louis, MO). The
lysates were then used for SDS-PAGE (10% polyacrylamide gels and
PVDF membranes, Pierce, Rockford, IL). Immunoblots were per-
formed following the manufacturer's recommendations. The follow-
ing antibodies were used: pERK1/2 (Cat # 9101 Cell Signaling,
Danvers, MA), ERK1/2 (Cat # 9102 Cell Signaling, Danvers, MA), p21
(Cat # OP68 EMD San Diego California), anti-TGFBR1 (H-100
antibody; sc-904, 1;200), HRP-goat anti-mouse (Cat # SC 2031)
and donkey anti-rabbit (Cat # SC 2317) (Santa Cruz Biotechnology).
A commercial ECL kit (RPN 3004, GE Healthcare, Piscataway, NJ) was
used to detect the HRP-labeled secondary antibodies and the signal
was detected using autoradiography. Reagents used in conjunction
with this kit included n-butyric acid sodium salt (Cat# B-5887),
Luminol (Cat# A8511), and p-coumaric acid (Cat# C9008) (Sigma-
Aldrich, St. Louis, MO).
2.6. PIK3/AKT speciﬁc ELISA
Phosphorylated AKT was detected using a commercially available
ELISA assay (SuperArray, SABiosciences, Frederick, MD). Ten thousand
cells/well were seeded in a 96 well plate, and were treated with
different concentrations of RG-115819 in order to differentially induce
the expression of the TGFBR2 transgene. TGF-β (10 ng/ml) was then
added to the cells and the cells were harvested after 48 h. The ELISA
was performed following the manufacturer's recommendations (Cat#
FE-001 SuperArray), and read in a plate reader at 450 nm (VERSAmax,
Molecular Devices, Sunnyvale, CA).
2.7. Quantitative RT-PCR
One microgram of RNA extracted from V-400 and V-400R2, was
reverse transcribed using oligo d(T) priming and Superscript-II
reverse transcriptase (Invitrogen) and 2 nM dNTPs following the
manufacturer's protocol. TaqMan On-Demand primers and probes
were used to determine the relative expression levels of CDKN1A/p21
(Assay number Hs99999142_m1, Applied Biosystems, Foster City, CA)
and 18S in all samples (Assay number Hs99999901_s1, Applied
Biosystems). The reactions were run in triplicate in the ABI Prism 7700
detection system (Applied Biosystems), and results were analyzed
with SDS 2.1 software.2.8. Apoptosis assays
Apoptosis was measured with two different assays: the Cell Death
ELISA assay (Roche, Cat# 11 774 425 001), which detects histone-
complexed DNA fragments, following the manufacturer's protocol,
and the Caspase-Glo Luciferase-based reporter assay, which measures
caspase 3 and 7 activity (Promega, Catalog number TB323) following
the manufacturer's protocol.
3. Results
3.1. Generation of a colorectal cancer cell line with precisely regulatable
TGFBR2 expression
In order to assess the effect of the expression level of TGFBR2 on
the activation of TGF-β signaling pathways, we employed the
RheoSwitchR gene regulation system that can precisely regulate the
transgene of interest [28,29,31]. An HA-tagged TGFBR2 transgene was
cloned into a lentiviral expression vector and used to generate
lentivirus for transducing the target cell line, V-400. This cell line lacks
a functional TGF-β receptor and becomes TGF-β responsive when it is
reconstituted with TGFBR2 [27]. (See Materials and methods section
for information on the plasmids used.) The V-400 cells were
transduced with TGFBR2, and clones expressing the RheoSwitchR
receptor and TGFBR2 transgene were selected and then assessed for
TGF-β responsiveness using the 3TP-lux or CAGA reporters. Two
clones displayed a linear dose–response of 3TP-Lux activity in relation
to RG-102240 concentration (Fig. 2).
The expression levels of the TGFBR2 transgene were then assessed
by FACS analysis in order to determine the amount of TGFBR2
expressed on the surface of the transduced cells. Immunoblotting of
total protein lysates from the cells for the HA-tagged TGFBR2
transgene conﬁrmed the results of the FACS analysis but does not
demonstrate the same linear response to the RG-115819 because of
the lower precision of immunoblotting to detect small differences in
protein expression (Fig. 3A, B). Clones 1 and 2 showed a linear increase
in 3TP-Lux induction and TGFBR2 transgene expression after treat-
ment with increasing concentrations of RG-115819 (Fig. 3A). A linear
dose–response for TGFBR2 expression between 0.04 μM to 1 μM RG-
115819 was demonstrated, and thus this range of RG-115819 was used
for the subsequent experiments. We did not observe any change in
TGFBR1 expression with increasing concentrations of RG-115819,
which led us to interpret that any RG-115819 dependent phenomenon
were strictly the result of changes in the expression level of TGFBR2
(Fig. 3C).
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mediated expression of CDKN1A/p21
TGF-β can regulate the expression of a variety of genes that control
a myriad of cell responses including proliferation, apoptosis, differ-
entiation, etc. [30,32,33]. A signiﬁcant question that arises is how the
speciﬁcity of the response is determined. One of the TGF-β regulated
genes that highlights the issues related to control of the speciﬁcity of
the TGF-β response is the CDK inhibitor CDKN1A/p21, which plays
an important role in several cellular processes including apoptosis,
cell cycle arrest, induction of cell differentiation, and cellular
senescence [32,34]. Thus, we assessed the regulation of CDKN1A/
p21 expression in the setting of different levels of TGFBR2 expression
to determine if the regulation of the expression of the TGF-β recep-
tor may be a mechanism through which TGF-β mediated responses
are regulated. In order to determine how changes in the expression
levels of TGFBR2 affect the expression of CDKN1A/p21, V-400R2 cells
were treated for 24 and 48 h with four different concentrations of
RG-115819 (0.04, 0.08, 0.4 and 1 μM) and TGF-β (10 ng/ml). The
induction of CDKN1A/p21 expression was assessed using a CDKN1A/
p21 luciferase reporter [35]. CDKN1A/p21 reporter activity wasFig. 4. CDKN1A/p21 expression in V-400R2 cells after treatment with different
concentrations of RG-115819. V-400R2 clone 1 was treated with four different con-
centrations of RG-115819 (0.04; 0.08; 0.4 and 1 μM) and then CDKN1A/p21 expression
was assessed. (A) CDKN1A/p21 luciferase reporter activity after 48 h of RG-115819.
Induction of CDKN1A/p21 is present at 48 h with a linear dose–response being evident
at 48 h. (B) After 48 h of treatment with RG-115819, a dose related increase in CDKN1A/
p21 protein expression is present, consistent with the CDKN1A/p21 reporter assay
results. Densitometry was performed on the bands, and these results were normalized
for loading using the densitometry values from the corresponding actin immunoblot.
The densitometry revealed a linear increase in band density that correlated with
increasing RG-115819 concentration [93 (0 μM), 90 (0.04 μM), 101 (0.08 μM), 121
(0.5 μM) and 159 (1 μM)]. Image J software (NIH) was used for the densitometry
analysis.
Fig. 3. The expression of cell surface TGFBR2 in V-400 after treatment with RG-115819.
(A) FACS analysis using an anti-HA antibody was performed after treatment with
different doses of RG-115819 (0 μM–1.0 μM). An increased amount of cell surface
TGFBR2 is detected with the increasing RG-115819 doses. M1 designates the
ﬂuorescence signal detected in the parental V-400 cell line. Of note, although no HA-
tagged TGFBR2 can be detected with this technique after 0.04 μMRG-115819 treatment,
as shown in Fig. 1, TGF-β induced gene expression is detected with this concentration of
RG-115819 indicating that the transgenic receptor is present on the cell surface with
this dose of RG-115819. The untreated V-400R2 clones showed the same level of
ﬂuorescence as that seen in the parental V-400 cell line. (B) Immunoblotting using an
anti-HA antibody was performed after treatment with different doses of RG-115819
(0 μM–1.0 μM). An increased amount of cell surface TGFBR2 is detected when
comparing the untreated V-400R2 cell line to the cell line treated with the increasing
RG-115819 doses although the resolution of immunoblotting does not reveal the
changes in expression level as accurately as does ﬂow cytometry. (C) Immunoblotting
using an anti-TGFBR1 antibody after treatment with different doses of RG-115819
(0 μM–1.0 μM) reveals no signiﬁcant change in TGFBR1 expression with RG-115819
treatment. Expression of actin was assessed to control for protein loading.increased at 24 h but no correlation between increasing TGFBR2
expression and reporter activity was observed at that time point. At
48 h, a direct relation between TGFBR2 expression level and CDKN1A/
p21 reporter activity was apparent (Fig. 4A). Importantly, no basal
CDKN1A/p21 reporter luciferase activity was detected in the V-
400R2 without RG-115819 or in the parental cell line V-400
(Fig. 4A). CDKN1A/p21 protein expression also correlated with the
CDKN1A/p21 luciferase reporter activity (Fig. 4B). Localization of p21
was also assessed in light of the possibility that MAPK signaling could
regulate p21 nuclear localization in these cells. We observed increased
nuclear p21 in association with increased p21 expression induced by
increased TGFBR2 expression. These results suggest that the increased
p21 is being retained in the nucleus despite the presence of increased
activated ERK and that p21 is acting to affect the behavior of the cell
through actions on gene transcription (Supplemental Fig. 1).
3.3. TGFBR2 levels can differentially affect MAPK–ERK pathway
activation and Smad pathway activation
The expression of CDKN1A/p21 is regulated by several signaling
pathways and transcription factors, including the Smad signaling
pathway, ERK signaling pathway, myc, etc. [23,36–38]. In light of
the differing effect of low and high levels of TGFBR2 expression on
CDKN1A/p21 expression, we assessed the effect of different levels of
TGFBR2 expression on the activation status of Smad and nonSmad
signaling pathways. V-400R2 cells were treated with RG-115819 (0.4–
1.0 μM) and assessed for MAPK–ERK activation at 24 and 48 h. ERK
activation was not present at 24 h but was present at 48 h after
treatment with RG-115819 and TGF-β (Fig. 5A). The level of
phosphorylated ERK directly correlated with the expression level of
Fig. 6. CDKN1A/p21 expression levels are regulated byMAPK/ERK in V-400R2 cells. The
V-400R2 cell line was cultured in the presence of RG-115819, TGF-β (10 ng/ml) and the
MAPK/ERK inhibitor U0126 for 48 h. (A)No increase inphosphorylated ERK (pERK) or in
CDKN1A/p21 expression is detected in V-400R2 cells treated with the MAPK/ERK
inhibitor demonstrating CDKN1A/p21's expression is regulated by ERK in a TGFBR2
dependent manner. The activation of ERK is considerably reduced due to the presence of
the inhibitor. Of note, total levels of ERK were not altered. CDKN1A/p21 and pERK are
detectable with vehicle only treatment, which is likely a consequence of a nonspeciﬁc
effect of the U0126 vehicle. (B) Inhibition of TGF-βmediated 3TPLux reporter activity by
Smad7 occurs with all concentrations of ligand. V-400R2 cells were transfected with a
plasmid expressing Smad7 in order to inhibit the Smad dependent pathway, and then
transfected with the 3TP-Lux reporter. The dose dependent relation between luciferase
activity and TGFBR2 is blocked by Smad7 demonstrating Smad7 is blocking Smad
mediated transcription. (C) Smad7 does not inhibit TGFBR2 dependent increases in
CDKN1A/p21 luciferase reporter activity. V-400R2 cells were transfected with both
Smad7 and the CDKN1A/p21 reporter assay. Interestingly, no signiﬁcant changes in the
activity of the CDKN1A/p21 luciferase reporter is detected after Smad7 transfection
demonstrating that the expression level of TGFBR2 does not regulate CDKN1A/p21
expression through Smad signaling. The intensity of the bands was determined using
densitometry as described in the prior ﬁgure legends. Densitometry for phosphorylated
ERK revealed the following values: 120 (0 μM), 130 (0.04 μM), 126 (0.08 μM), 145
(0.5 μM) and 131 (1 μM) and for p21: 130 (0 μM), 135 (0.04 μM), 142 (0.08 μM), 142
(0.5 μM) and 145 (1 μM).
Fig. 5. ERK and Smad activation after treatment with RG-115819 demonstrates a direct
dose relation of RG-115819 to activation of both pathways. (A) Immunoblotting for
phosphorylated ERK1/2 (pERK) was performed on V-400R2 treated for 48 h with
RG-115819 (0 μM–1 μM). A dose-related increase in pERK in the cells is demonstrated.
Total ERK levels reveal no differences with RG-115819 treatment. (B) Immunoblot
results of phosphorylated Smad2 (pSmad2) after 48 h of treatment with RG-115819 also
reveal a dose-related increase in the pSmad2 levels with doses greater than 0.08 μM.
The amount of increase in pSmad2 is less than that observed for pERK. Densitometry
was performed on the pERK bands, and these results were normalized for loading using
the densitometry values from the corresponding actin immunoblot. The densitometry
revealed a linear increase in band density that correlated with increasing RG-115819
concentration [60 (0 μM), 90 (0.04 μM), 101 (0.08 μM), 121 (0.5 μM) and 159 (1 μM)].
Image J software (NIH) was used for the densitometry analysis.
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we also assessed the effect of TGFBR2 expression on PI3K pathway
activation and found that phosphorylated AKT is present in the
parental cell line and that TGF-β does not induce an increase in
phosphorylated AKT in the TGFBR2 reconstituted cell line at any level
of TGFBR2 expression (data not shown). After assessing the effect of
TGFBR2 on the MAPK–ERK pathway, we next assessed the activation
state of the Smad signaling pathway. Unlike with the MAPK–ERK
pathway, Smad2 phosphorylation was increased with moderate to
high levels of TGFBR2 but not with low expression levels of the
receptor. There was also a modest increase in phosphorylated Smad2
with increasing levels of TGFBR2 expression, but the range of
increased phosphorylated Smad2 was more limited than that for
phosphorylated ERK1/2 (Fig. 5B). The functional effect of the increase
in phosphorylated Smad2 can be observed by a linear increased in
CAGA luciferase reporter activity, which is speciﬁc for Smad mediated
transcription (Fig. 8).
3.4. TGF-β mediated regulation of CDKN1A/p21 expression is dependent
on Smad and MAPK–ERK activation
It has been previously shown in other cell line systems that the
MAPK–ERK pathway can control the expression of CDKN1A/p21 and
that TGF-β can regulate CDKN1A/p21 through the MEK pathway
[30,39,40]. Consequently we assessed the effect of inhibition of ERK
activation on the ability of TGF-β to induce CDKN1A/p21 expression in
the V-400R2 cell line in order to conﬁrm that this was also true in this
colorectal cancer cell line. TGF-β mediated activation of ERK was
inhibited with the selective MAPK inhibitor U0126 (5 μM) in V-400R2
cells treatedwith RG-115819 (0.04–1.0 μM) and TGF-β (10 ng/ml). The
induction of TGFBR2 expression induced the expression of CDKN1A/
p21, but blockade of the MAPK–ERK pathway prevented the dif-
ferential increase in CDKN1A/p21 expression observed in the prior
studies. These results suggest that CDKN1A/p21 expression is
regulated by both MAPK–ERK and nonMAPK–ERK signaling pathways
(Fig. 6A). We next assessed the effect of TGF-β mediated Smad
pathway activation on the expression of CDKN1A/p21 using the
inhibitory Smad, Smad7. Transfection of the V-400R2 cells with
SMAD7 almost completely blocked the induction of the CAGA
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CDKN1A/p21 reporter activity, but did not prevent the linear increase
in CDKN1A/p21 expression observed with increasing TGFBR2 expres-
sion indicating the TGF-β mediated regulation of the precise
expression levels of CDKN1A/p21 in V-400R2 is regulated predomi-
nantly by nonSmad signaling (Fig. 6B, C).
3.5. TGFBR2 expression levels regulate the ability of TGF-β to induce
CDKN1A/p21 mediated apoptosis
In light of our results showing that TGFBR2 expression directly
correlates with increased ERK activation and CDKN1A/p21 expression,
we carried out a series of studies to determinewhether the expression
level of TGFBR2 can directly affect the ability of TGF-β to induce
apoptosis. The V-400R2 cell line was treated with RG-115819 in order
to induce low and high levels of TGFBR2 and then assessed for TGF-β
mediated apoptosis. A direct relationship between TGFBR2 expression
and apoptosis was demonstrated showing that high levels of TGFBR2
are permissive for TGF-β mediated apoptosis (Fig. 7). These results
suggest that TGF-β can mediate apoptosis in the V-400R2 cell line
through the induction of the MAPK–ERK pathway and subsequent
increase in CDKN1A/p21 expression. Thus, TGFBR2 levels may be a
mechanism for determining whether cells are sensitive or resistant
to TGF-βmediated apoptosis.
In order to establish if the induction of increased CDKN1A/p21
resulting from the increased TGFBR2 expression and ERK activation is
a central mechanism for TGF-β mediated apoptosis in the V-400R2
cells, CDKN1A/p21 expression was inhibited with p21-siRNA in the
presence of low and high levels or TGFBR2 and TGF-β (10 ng/ml)
(Fig. 8A). Interestingly we found that inhibition of CDKN1A/p21
prevented the increase in apoptosis observed with increased TGFBR2
levels providing support for CDKN1A/p21 regulation being a mechan-
ism for TGF-β mediated apoptosis in colon cancer (Fig. 8B). However,Fig. 7. High expression levels of TGFBR2 induce apoptosis in V-400R2 cells. (A) TGF-β
mediated apoptosis was assessed using the Cell Death ELISA in V-400R2 treated with
RG-115819 and TGF-β (10 ng/ml). TGF-β mediated apoptosis is increased with doses
of RG-115819 greater than 0.4 μM indicating that moderate-high levels of TGFBR2
and CDKN1A/p21 permit TGF-β to induce apoptosis in these cells. (B) TGF-β
mediated apoptosis assessed by caspase 3 and 7 activity conﬁrms the results
obtained with the Cell Death ELISA assay showing apoptosis directly correlates with
TGFBR2 levels.
Fig. 8. TGFBR2 dependent apoptosis is suppressed by CDKN1A/p21 siRNA. (A) siRNA for
CDKN1A/p21 suppresses CDKN1A/p21 reporter luciferase activity in the V-400R2 cell
line. A dose related increase in luciferase reporter activity in the siRNA control treated
cell line is demonstrated. (B) Apoptosis in V-400R2 was measured using the Cell Death
ELISA (Roche) after 48 h of treatment with TGF-β (10 ng/ml). Treatment with the
CDKN1A/p21 siRNA inhibits the TGFBR2 dependent induction of apoptosis, which is
seen in the siRNA control treated cells. (C) TGF-β mediated apoptosis is inhibited by
SMAD7. Apoptosis was induced by TGF-β in the V-400R2 cell line after transfection
with SMAD7. SMAD7 abrogates the increased apoptosis observed in the V-400R2 cells
treated with increasing concentrations of RG-115819.we also observed that inhibition of Smad signaling with SMAD7
impaired TGF-β mediated apoptosis presumably through a p21 inde-
pendent mechanism, given that we did not observe an effect of
SMAD7 on p21 expression. These results demonstrate TGFBR2 can
regulate apoptosis through both p21 dependent and independent
mechanisms (Fig. 8C).
4. Discussion
TGF-β can induce a variety of biological responses in cells, and
these responses appear to be dependent on the cell type and context
of the cell [41]. Some of the mechanisms that appear to play a role
in determining the speciﬁcity of the response of a cell to TGF-β include
signal pathway cross-talk, regulation of the expression levels of
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of transcription factor complexes [20,33]. In addition, over a decade
ago, Derynck and Feng proposed the possibility of a receptor threshold
model for determining the speciﬁcity of TGF-β's effects. This model
proposes that there is a critical expression level of the TGF-β receptor
that determines the speciﬁc TGF-β responses of a cell [42,43]. Several
lines of indirect evidence have supported this model, but to date there
has been no direct assessment of this hypothesis [8,43–47]. We now
provide direct evidence that the regulation of the expression level of
TGFBR2 can affect the speciﬁcity of the TGF-β response. We have
shown that the activation of the Smad and nonSmad signaling
pathways can be modulated by the expression level of TGFBR2 and
that the activation state of the nonSmad signaling pathway principally
determines whether TGF-β can induce CDKN1A/p21 mediated apop-
tosis in an epithelial cell line.
TGF-β and the TGF-β receptors are expressed in nearly all cell types
and in developing and adult organisms. In embryonic development
there is clear evidence that the concentration of active TGF-β and the
extent of TGF-β signal pathway activation is tightly regulated and
creates a gradient of responses that determines cell fate, among other
things [41]. The majority of these studies have provided indirect and
correlative evidence that the concentration of the ligands, receptors, and
intracellular Smad proteins can determine the speciﬁc response of a cell
to TGF-β. Further indirect evidence that the expression level can affect
the speciﬁcity of the TGF-β response comes from studies of dominant
negative TGFBR2 transgenes and chimeric receptors [22,24,48–50]. Our
studies now provide direct evidence that the TGFBR2 expression level
can regulate the intensity of activation of the Smad and nonSmad
signaling pathways. Furthermore, the differences in activation of the
Smad and MAPK–ERK pathways at different TGFBR2 expression levels
suggests that not only can the level of TGFBR2determine the intensity of
pathway activation but also which pathways are activated [33]. The
differential regulation of the post-TGF-β receptor pathways would be
expected to lead to differences in transcription factor activation and
transcription factor complex formation, which could then induce
different patterns of gene expression.
Although the model above predicts that TGFBR2 expression levels
will cause the differential expression of a variety of genes, we chose to
speciﬁcally study CDKN1A/p21 because of its well-demonstrated
regulation by TGF-β and because of its clear biological role in the
inhibition of proliferation and induction of apoptosis. In addition,
CDKN1A/p21 is regulated by TGF-β both by Smad and nonSmad
signaling pathways and thus allows an assessment of the effect of
Smad and nonSmad signaling on gene regulation [10,51]. Our data
suggest that CDKN1A/p21 is regulated by both the MAPK–ERK and
Smad signaling pathways, which is true of other genes, such as FURIN
[32]. These pathways may cross-talk at the level of Smad phosphor-
ylation, nuclear localization of Smads, or at the level of transcription
factor complex formation [33,52,53]. The differential activation of
MAPK–ERK and Smad pathways suggests that at low levels of TGF-β
receptor activation the nonSmad signaling pathways predominate
over the Smad signaling pathways in determining the effect of TGF-β
on the cell. The differences in activation of the MAPK and Smad
pathways likely reﬂect the fact that the MAPK signaling pathway is
a catalytic pathway whereas the Smad pathway is non-catalytic [8].
An interesting observation related to this explanation for the
differential activation of the Smad and nonSmad pathways is the fact
that in V-400R2 the MAPK–ERK pathway appears to be the
predominant pathway regulating the level of CDKN1A/p21 expression
whereas the Smad pathway has amoremodest effect. These results are
consistent with those of Hu et al. who observed a similar phenomenon
in the HaCaT keratinocyte cell line, but are in contrast to other studies
that have shown that both Smad and SP1 mediated signaling are
necessary for CDKN1A/p21 expression [20,30,54,55]. These differences
may reﬂect cell line speciﬁc differences in the expression of other
regulators of CDKN1A/p21, such as c-Myc or MIZ-1 [56,57].There are several limitations related to our studies of the effect of
TGFBR2 expression levels on TGF-β signaling. At this time, it is not
clear whether the effects we have observed involve direct or indirect
mechanisms for regulating the Smad and nonSmad signaling path-
ways. This limitation reﬂects our incomplete understanding of the
mechanisms through which TGF-β affects the nonSmad signaling
pathways [20]. In addition, we have not assessed the effect of TGFBR2
expression levels on the regulation of other signaling pathways and
cannot exclude the possibility that these pathways are also playing a
role in the regulation of CDKN1A/p21 and apoptosis that is affected by
the expression level of the TGF-β receptor. Nonetheless, our results
demonstrate that TGF-β receptor levels can regulate MAPK–ERK
activation and that the control of this pathway has a central role in
regulating CDKN1A/p21 expression and CDKN1A/p21 mediated apop-
tosis in the V-400R2 cell line.
Our results have several implications for the role of TGF-β in
regulating normal cellular responses and for the role of TGF-β in
cancer. The relevance of the effect of TGFBR2 expression levels on the
regulation of TGF-β's effects on cells is appreciated in light of prior
studies that have shown decreased TGFBR2 expression in a variety of
cancers and in some inﬂammatory states [58]. In fact, many cancers
have suppressed TGFBR2 expression without detectable mutations in
any of the TGF-β signal pathway genes [59,60–62]. In these cancers
with an intact TGF-β receptor that is expressed at a low level, TGF-β
appears to have the potential to act as an oncogene as well as a tumor
suppressor gene [63]. This paradoxical role of TGF-β has been asso-
ciated with its ability to activate Smad independent pathways (MAPK,
PI3K and Rho) and with the modulation of TGF-β signaling pathway
activation through interactionswith other signaling pathways induced
by mutated oncogenes and tumor suppressor genes [8,18,21,22]. Our
results suggest that an additional mechanism by which TGF-β may
mediate paradoxical effects on cells is through the down-regulation of
the expression of TGFBR2, which could differentially activate signaling
pathways and alter the gene expression patterns of the cells. Thus,
our results not only demonstrate that the expression level of TGFBR2
can inﬂuence the pathway activation status of TGF-β signaling
pathways and the speciﬁc response of cells to TGF-β, but also that
the regulation of the expression level is a plausible mechanism for
the paradoxical effects of TGF-β on cancer cells. In summary, regu-
lation of TGFBR2 expression levels is an additional mechanism for
controlling the speciﬁcity of TGF-β's effects on cells and is a potential
mechanism for the paradoxical effects of TGF-β observed in cancer.
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